ARIScience
ARIScience is at the forefront of drug discovery, leveraging a unique combination of AI, quantum chemistry, computer vision, and biochemistry to develop novel small molecule drugs. Their mission is to reduce the burden of human disease by discovering therapeutics that interrupt disease pathways. With a focus on neurodegenerative, inflammatory, and infectious diseases, ARIScience employs cutting-edge in silico methods to efficiently identify and optimize drug candidates. Their commitment to innovation and collaboration with leading institutions positions them to make a significant impact on human health.
What We Do
ARICore is a software library that provides high-performance computing capabilities for complex numerical functions, including 1D, 2D, and 3D integrations, root discovery, and more. It is designed to enhance computational tasks with speed and accuracy.
BioTD is an in silico platform that uses high-performance computing to simulate biological systems and predict the behavior of small molecules, aiding in drug discovery and development.
Digital Health Technologies
Show More (1)Biologics
Services
Key People
Clinical Research Expert, Global Health Expert
Acute Care Expert
Clinical Care Expert Hospitalist
In-vitro Assay Expert
News & Updates
ARIScience presented their OIRD countermeasure results at the NIH/NIDA/BARDA conference on December 18, 2024.
In April 2023, ARIScience was awarded an advanced protein impact via small molecule research contract by the United States Biomedical Advanced Research and Development Agency, successfully completed in October 2024.